Literature DB >> 27063617

Relapses in multiple sclerosis: Relationship to disability.

Douglas S Goodin1, Anthony T Reder2, Robert A Bermel3, Gary R Cutter4, Robert J Fox5, Gareth R John6, Fred D Lublin7, Claudia F Lucchinetti8, Aaron E Miller7, Daniel Pelletier9, Michael K Racke10, Bruce D Trapp11, Timothy Vartanian12, Emmanuelle Waubant13.   

Abstract

Multiple sclerosis (MS) is a recurrent inflammatory disease of the central nervous system, which ultimately causes substantial disability in many patients. A key clinical feature of this disease is the occurrence of relapses, consisting of episodes of neurological dysfunction followed by periods of remission. This review considers in detail the importance of the occurrence of relapses to the ultimate course of MS and the impact of relap setreatment (both acutely and prophylactically) on the long-term outcome for individuals. The ultimate goal of therapy in MS is the reduction of long-term disability. Clinical trials in MS, however, typically only extend for a very short time period compared to the time it takes for disability to evolve. Consequently, short-term outcome measures that are associated with, and predict, future disability need to be identified. In this regard, not only are relapses a characteristic feature of MS, they have also been proven to be associated with the occurrence of long-term disability. Moreover, treatments that reduce the number and severity of these attacks improve the long-term prognosis.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Disability; Lesion; MRI; Multiple sclerosis; Relapse; Treatment

Mesh:

Year:  2015        PMID: 27063617     DOI: 10.1016/j.msard.2015.09.002

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  9 in total

1.  Influenza infection triggers disease in a genetic model of experimental autoimmune encephalomyelitis.

Authors:  Stephen Blackmore; Jessica Hernandez; Michal Juda; Emily Ryder; Gregory G Freund; Rodney W Johnson; Andrew J Steelman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

Review 2.  The Relevance of Neuroimaging Findings to Physical Disability in Multiple Sclerosis.

Authors:  Rahşan Göçmen
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

3.  Effect of Health Care Providers' Focused Discussion and Proactive Education About Relapse Management on Patient Reporting of Multiple Sclerosis Relapse.

Authors:  Royce W Waltrip; Nancy Mahler; Alina Ahsan; Leslie B Herbert
Journal:  Int J MS Care       Date:  2021-02-08

Review 4.  Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate.

Authors:  Lori Mayer; Mary Kay Fink; Carrie Sammarco; Lisa Laing
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

5.  Environmental temperature and exercise modality independently impact central and muscle fatigue among people with multiple sclerosis.

Authors:  Geetika Grover; Michelle Ploughman; Devin T Philpott; Liam P Kelly; Augustine J Devasahayam; Katie Wadden; Kevin E Power; Duane C Button
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-12-21

Review 6.  Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis.

Authors:  Bernard M J Uitdehaag
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

7.  Leveraging electronic health records data to predict multiple sclerosis disease activity.

Authors:  Yuri Ahuja; Nicole Kim; Tianxi Cai; Zongqi Xia; Liang Liang; Tianrun Cai; Kumar Dahal; Thany Seyok; Chen Lin; Sean Finan; Katherine Liao; Guergana Savovoa; Tanuja Chitnis
Journal:  Ann Clin Transl Neurol       Date:  2021-02-24       Impact factor: 4.511

8.  Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model.

Authors:  Fay Probert; Daniel C Anthony; Tianrong Yeo; Halwan Bayuangga; Marcus Augusto-Oliveira; Megan Sealey; Timothy D W Claridge; Rachel Tanner; David Leppert; Jacqueline Palace; Jens Kuhle
Journal:  J Neuroinflammation       Date:  2022-10-09       Impact factor: 9.587

9.  Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.

Authors:  Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Bruno Brochet; Robert T Naismith; Anthony Traboulsee; Jerry S Wolinsky; Shibeshih Belachew; Harold Koendgen; Victoria Levesque; Marianna Manfrini; Fabian Model; Stanislas Hubeaux; Lahar Mehta; Xavier Montalban
Journal:  Neurology       Date:  2020-07-20       Impact factor: 9.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.